J&J expects double-digit 2023 profit growth after Kenvue spinoff
(Reuters) -Johnson & Johnson on Wednesday forecast double-digit profit growth for 2023 after spinning off...
N2:PHMR
N2:ACB
N2:CMPNY
N2:DEAL1
N2:EUROP
N2:HEA
N2:IE
N2:INSR
N2:JUDIC
N2:MONOP
N2:MRG
N2:NAMER
N2:NEWS1
N2:PHAG08
N2:PHAR1
N2:PHMR
N2:PUBL
N2:REGS
N2:US
N2:WASH
US FTC suspends challenge to block Amgen’s $27.8 billion deal for Horizon Therapeutics
(Reuters) -The U.S. Federal Trade Commission (FTC) has suspended its challenge of Amgen’s $27.8 billion...
N2:BIODRG
N2:CMPNY
N2:COMDIS
N2:COVID
N2:CPROD
N2:DISEAS
N2:GEN
N2:HEA
N2:HECA
N2:HUMDIS
N2:INFDIS
N2:MEDREG
N2:MRCH
N2:NAMER
N2:PHMR
N2:PUBHEA
N2:PUBL
N2:US
N2:VACCIN
US govt awards $1.4 billion for development of new COVID therapies, vaccines
(Reuters) – The U.S. government said on Tuesday it had awarded $1.4 billion for the...
N2:BLR
N2:CMPNY
N2:CPROD
N2:DRUDEV
N2:HEA
N2:HEADMI
N2:HECA
N2:MRCH
N2:MTPIX
N2:NAMER
N2:PHAG08
N2:PHAR
N2:PHAR1
N2:PHMR
N2:PUBL
N2:PXP
N2:RES
N2:RESF
N2:RHEUMA
N2:SCI
N2:TOPNWS
N2:US
AbbVie trims forecast for Humira sales drop on favorable coverage
By Leroy Leo and Patrick Wingrove (Reuters) -AbbVie on Thursday trimmed its 2023 view for...
N2:BLR
N2:CMPNY
N2:COVID
N2:DRUGEN
N2:HEA
N2:HECA
N2:MEDDTE
N2:MEDQ
N2:MEDQ1
N2:MRCH
N2:MTPIX
N2:NAMER
N2:NEWS1
N2:PHAG08
N2:PHAR1
N2:PHMR
N2:PUBL
N2:PXP
N2:RES
N2:RESF
N2:US
N2:VACCIN
J&J upbeat on 2023 as devices rebound post-COVID, shares jump
By Bhanvi Satija and Patrick Wingrove (Reuters) -Johnson & Johnson on Thursday expressed optimism for...
N2:CMPNY
N2:DEMENT
N2:HEA
N2:MEDCON
N2:MEDREG
N2:MRCH
N2:MRCH1
N2:NAMER
N2:PHMR
N2:PUBL
N2:SCI
N2:US
Acumen’s Alzheimer’s drug passes initial safety test
By Julie Steenhuysen CHICAGO (Reuters) – An experimental Alzheimer’s disease drug developed by Acumen Pharmaceuticals...
N2:ASIA
N2:BIOPH
N2:CMPNY
N2:CPROD
N2:DEMENT
N2:DRUDEV
N2:HEA
N2:HEADMI
N2:INSR
N2:JP
N2:MEDREG
N2:MRCH
N2:MTGFX
N2:MTPIX
N2:NAMER
N2:NEWS1
N2:PHAG08
N2:PHAR1
N2:PHMR
N2:PUBL
N2:SCI
N2:TOPNWS
N2:US
US FDA grants standard approval of Eisai/Biogen Alzheimer’s drug
By Deena Beasley and Julie Steenhuysen LOS ANGELES (Reuters) -Eisai and Biogen’s Leqembi won a...
N2:BREACA
N2:CH
N2:CMPNY
N2:CNCER
N2:DE
N2:ENDOCR
N2:EUROP
N2:FIN
N2:HEA
N2:MEDREG
N2:NAMER
N2:PHAG08
N2:PHAR1
N2:PHMR
N2:PUBL
N2:SCI
N2:US
N2:WEU
N2:WOMHEA
Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
By Ludwig Burger FRANKFURT (Reuters) – Novartis breast cancer drug Kisqali cut the risk of...
N2:ADVO
N2:CMPNY
N2:DEMENT
N2:EREP
N2:EXCLSV
N2:GERIAT
N2:HEA
N2:HECA
N2:MEDREG
N2:MTPIX
N2:NAMER
N2:NEUROL
N2:NEWS1
N2:PHAG08
N2:PHAR
N2:PHAR1
N2:PHMR
N2:PUBL
N2:SCI
N2:US
N2:WASH
Exclusive-US to build $300 million database to fuel Alzheimer’s research
By Julie Steenhuysen CHICAGO (Reuters) – The U.S. National Institute on Aging (NIA) is funding...